دورية أكاديمية
أعرض في EDS

Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting.

التفاصيل البيبلوغرافية
العنوان: Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting.
المؤلفون: Chadha M; Endocrinology, P.D. Hinduja Hospital, Mumbai, India., Das AK; Endocrinology, Pondicherry Institute of Medical Science, Puducherry, India., Deb P; Endocrinology, Krishna Institute of Medical Sciences, Hyderabad, India., Gangopadhyay KK; Endocrinology, Peerless Hospital, Kolkata, India., Joshi S; Endocrinology, Joshi Clinic and Lilavati Hospital and Research Centre, Mumbai, India., Kesavadev J; Jothydev's Diabetes and Research Center, Thiruvananthapuram, India., Kovil R; Department of Diabetology, Dr Kovil's Diabetes Care Centre, Mumbai, India., Kumar S; Endocrinology, Sir Ganga Ram Hospital, New Delhi, India., Misra A; Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, National Diabetes, Obesity and Cholesterol Foundation (N-DOC), Diabetes Foundation (India) (DFI), New Delhi, India., Mohan V; Dr Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Chennai, India. drmohans@diabetes.ind.in.
المصدر: Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2022 May; Vol. 13 (5), pp. 1097-1114. Date of Electronic Publication: 2022 Mar 25.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Healthcare Country of Publication: United States NLM ID: 101539025 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1869-6953 (Print) Linking ISSN: 18696961 NLM ISO Abbreviation: Diabetes Ther Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [New York] : Springer Healthcare, 2010-
مستخلص: The Asian-Indian phenotype of type 2 diabetes mellitus is uniquely characterized for cardio-metabolic risk. In the context of implementing patient-centric holistic cardio-metabolic risk management as a priority, the choice of various combinations of antidiabetic agents should be individualized. Combined therapy with two classes of antidiabetic agents, namely, dipeptidyl peptidase 4 inhibitors and sodium-glucose co-transporter-2 inhibitors, target several pathophysiological pathways. The wide-ranging clinical outcomes associated with this combination, including improvement of glycemia and adiposity, reduction of metabolic and vascular risk, safety, and simplicity for sustainable compliance, are extremely relevant to the Asian Indian patient population living with T2DM. In this review we describe the available evidence in detail and present a rational practical guidance for the optimum clinical use of this combination in this patient population.
(© 2022. The Author(s).)
References: Diabetes Care. 2020 Aug;43(8):1948-1957. (PMID: 33534728)
N Engl J Med. 2019 Jan 24;380(4):347-357. (PMID: 30415602)
Diabetes Ther. 2018 Feb;9(1):253-268. (PMID: 29313282)
Diabetes Care. 2018 Aug;41(8):1801-1808. (PMID: 29895557)
N Engl J Med. 2020 Oct 8;383(15):1425-1435. (PMID: 32966714)
Diabetes Care. 2015 Mar;38(3):376-83. (PMID: 25352655)
Diabetes Obes Metab. 2018 Sep;20(9):2200-2209. (PMID: 29766636)
Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102. (PMID: 30559235)
Int J Cardiol. 2013 Jul 15;167(1):87-93. (PMID: 22217485)
J Diabetes Investig. 2019 May;10(3):760-770. (PMID: 30412655)
Lancet Diabetes Endocrinol. 2018 Dec;6(12):966-978. (PMID: 30287102)
Diabetes Obes Metab. 2019 Jan;21(1):136-145. (PMID: 30091172)
J Pharmacol Exp Ther. 2014 Sep;350(3):657-64. (PMID: 24993361)
Circ J. 2017 Jan 25;81(2):227-234. (PMID: 28025462)
Diabetes Metab Syndr. 2022 Jan;16(1):102345. (PMID: 34920199)
J Diabetes Complications. 2016 Nov - Dec;30(8):1622-1630. (PMID: 27499458)
Diabetes Ther. 2021 Mar;12(3):843-861. (PMID: 33586120)
J Clin Endocrinol Metab. 2013 Jul;98(7):E1163-72. (PMID: 23633194)
Diabetes Obes Metab. 2018 May;20(5):1111-1120. (PMID: 29266675)
Diabetes Care. 2015 Nov;38(11):2009-17. (PMID: 26246458)
N Engl J Med. 2017 Aug 17;377(7):644-657. (PMID: 28605608)
N Engl J Med. 2013 Oct 3;369(14):1317-26. (PMID: 23992601)
Br J Clin Pharmacol. 2012 Jul;74(1):75-85. (PMID: 22242621)
Indian J Endocrinol Metab. 2015 May-Jun;19(3):311-3. (PMID: 25932383)
Diabetes Obes Metab. 2018 Feb;20(2):453-457. (PMID: 28786530)
JACC Heart Fail. 2018 Jan;6(1):8-17. (PMID: 29032139)
Lancet Diabetes Endocrinol. 2018 Dec;6(12):992-1002. (PMID: 30287104)
Br J Clin Pharmacol. 1999 Nov;48(5):643-8. (PMID: 10594464)
Adv Ther. 2017 Sep;34(9):2150-2162. (PMID: 28819835)
J Diabetes Investig. 2016 Sep;7(5):744-50. (PMID: 27180969)
Diabetologia. 2018 Oct;61(10):2108-2117. (PMID: 30132036)
N Engl J Med. 2019 Jun 13;380(24):2295-2306. (PMID: 30990260)
N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978)
Sci Rep. 2019 Sep 16;9(1):13296. (PMID: 31527625)
Endocr Pract. 2019 Jan;25(1):69-100. (PMID: 30742570)
J Diabetes Sci Technol. 2011 Jul 01;5(4):906-14. (PMID: 21880233)
Diabetologia. 2011 Dec;54(12):3022-7. (PMID: 21959957)
Diabetes Care. 2015 Mar;38(3):394-402. (PMID: 25633662)
JAMA. 2019 Jan 1;321(1):69-79. (PMID: 30418475)
PLoS One. 2011;6(11):e27861. (PMID: 22125632)
Diabetes Care. 2013 Aug;36 Suppl 2:S127-38. (PMID: 23882037)
Diabetes. 2009 Apr;58(4):773-95. (PMID: 19336687)
J Assoc Physicians India. 2004 Jun;52:468-74. (PMID: 15645957)
Diabetes Obes Metab. 2019 Feb;21(2):388-392. (PMID: 30146790)
Indian J Endocrinol Metab. 2017 Mar-Apr;21(2):341-354. (PMID: 28459036)
J Clin Med. 2021 Sep 09;10(18):. (PMID: 34575189)
Sci Rep. 2018 Mar 13;8(1):4466. (PMID: 29535389)
Expert Opin Pharmacother. 2015;16(18):2819-33. (PMID: 26583910)
Diabetol Metab Syndr. 2020 Mar 16;12:22. (PMID: 32190124)
Drug Des Devel Ther. 2014 May 05;8:431-46. (PMID: 24851042)
Ann N Y Acad Sci. 2013 Apr;1281:51-63. (PMID: 23317344)
Diabetes Obes Metab. 2012 Jan;14(1):83-90. (PMID: 21985634)
Diabetes Obes Metab. 2014 Feb;16(2):118-23. (PMID: 23859534)
Diabetologia. 2018 Oct;61(10):2155-2163. (PMID: 30066148)
Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1407-1417. (PMID: 27435042)
Herz. 2019 May;44(3):192-202. (PMID: 30805659)
Clin Pharmacokinet. 2014 Mar;53(3):213-225. (PMID: 24430725)
J Am Coll Cardiol. 2020 Feb 4;75(4):422-434. (PMID: 32000955)
Prim Care Diabetes. 2018 Jun;12(3):265-283. (PMID: 29482993)
N Engl J Med. 2015 Jul 16;373(3):232-42. (PMID: 26052984)
J Diabetes. 2020 Jul;12(7):556-557. (PMID: 32419360)
Indian J Pharmacol. 2016 Jul-Aug;48(4):347-349. (PMID: 27756941)
Postgrad Med J. 2015 Nov;91(1081):612-21. (PMID: 26453594)
Diabetes Obes Metab. 2018 Mar;20(3):740-744. (PMID: 29053207)
BMJ Open Diabetes Res Care. 2017 Nov 06;5(1):e000393. (PMID: 29188065)
Diabetes Care. 2015 Mar;38(3):384-93. (PMID: 25583754)
Adv Ther. 2018 Jul;35(7):1009-1022. (PMID: 29949041)
Diabetes Ther. 2019 Apr;10(2):393-428. (PMID: 30706366)
فهرسة مساهمة: Keywords: Asian Indian phenotype; Cardio-metabolic risk; Dipeptidyl peptidase-4 inhibitor; Fixed-dose combinations; Sodium-glucose cotransporter-2 inhibitor; Type 2 diabetes
تواريخ الأحداث: Date Created: 20220325 Latest Revision: 20220716
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8948458
DOI: 10.1007/s13300-022-01219-x
PMID: 35334083
قاعدة البيانات: MEDLINE
الوصف
تدمد:1869-6953
DOI:10.1007/s13300-022-01219-x